

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7005756

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BAUSCH HEALTH IRELAND LIMITED	10/05/2021
RECEIVING PARTY DATA	
Name:	SOLTA MEDICAL IRELAND LIMITED
Street Address:	3013 LAKE DRIVE
Internal Address:	CITYWEST BUSINESS CAMPUS
City:	DUBLIN
State/Country:	IRELAND
Postal Code:	24
PROPERTY NUMBERS Total: 4	
Property Type	Number
Application Number:	29720106
Application Number:	29720107
Application Number:	29720109
Application Number:	29720111
CORRESPONDENCE DATA	
Fax Number:	(202)408-4400
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	faxserve@finnegan.com
Correspondent Name:	FINNEGAN
Address Line 1:	901 NEW YORK AVENUE, N.W.
Address Line 4:	WASHINGTON, D.C. 20001
ATTORNEY DOCKET NUMBER:	10353.24, 25, 26, 27
NAME OF SUBMITTER:	CHARLENE WOODS
SIGNATURE:	/Charlene Woods/
DATE SIGNED:	11/03/2021
Total Attachments: 4	
source=20211005_Conf_Assignment_BIRL-SoltaIreland#page1.tif	
source=20211005_Conf_Assignment_BIRL-SoltaIreland#page2.tif	

source=20211005_Conf_Assignment_BIRL-Soltalreland#page3.tif

source=20211005_Conf_Assignment_BIRL-Soltalreland#page4.tif

PATENT

REEL: 058011 FRAME: 0908

CONFIRMATORY PATENTS ASSIGNMENT

This Assignment Agreement, dated as of October 5th, 2021 (the "Agreement"), is made by and between Bausch Health Ireland Limited, a company established and existing under the laws of Ireland having its registered office at 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland ("Assignor") and Solta Medical Ireland Limited, a company established and existing under the laws of Ireland having its registered office at 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland ("Assignee").

WHEREAS, the patent applications and granted patents set forth on **Schedule A** (collectively, the "Assigned Patents") were transferred from Assignor to Assignee by virtue of the Re-organization Agreement dated 8 April 2021, and such rights are now owned solely by Assignee; and

WHEREAS, pursuant to this Agreement, Assignor desires to assign, convey and transfer, and Assignee desires to receive, all of Assignor's legal title to the Assigned Patents.


NOW, THEREFORE, in consideration of the mutual promises set forth in this Agreement and for the other good and valuable consideration, the receipt of which is hereby acknowledged, the parties hereby agree as follows:

1. Assignment of Assigned Patents. Assignor hereby assigns, conveys and transfers to Assignee, and Assignee hereby accepts, all of Assignor's right, title and interest in and to (i) the Assigned Patents and (ii) all benefits, privileges, causes of action, common law rights, and remedies relating thereto throughout the world, including, without limitation, all of Assignor's rights to (a) apply for and maintain all registrations, renewals and/or extensions thereof, (b) bring actions and recover damages for past, present and future infringement or other violation thereof, and (c) grant licenses or other interests therein.
2. Cooperation. At Assignee's sole cost and expense, Assignor shall execute and deliver such other documents and take all other commercially reasonable actions which Assignee, its successors and/or assigns, may reasonably request to effect the terms of this Assignment, including its recordation in relevant state and national patent offices.
3. Due Authorization. Assignor hereby authorizes and requests the Commissioner of Patents of the United States and any other official of any applicable governmental authority to (a) record Assignee as assignee and owner of the entire right, title and interest in and to the Assigned Patents and (b) issue any and all registrations from any and all applications for registration included in the Assigned Patents to and in the name of Assignee.
4. Successors and Assigns. This Agreement and all of its provisions shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns.
5. Governing Law; Jurisdiction. This Agreement shall be governed in all respects by the laws of the State of New York, without giving effect to the principles of conflicts of law thereof.
6. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.

{signature page follows}

IN WITNESS WHEREOF, the parties have caused this instrument to be duly executed and delivered as of the date first written above.

Bausch Health Ireland Limited,

By: 

Name: Roger McGrath

Title: Director

Solta Medical Ireland Limited,

By: 

Name: P. Graham Stuart

Title: Executive Director IP

SCHEDULE A

ASSIGNED PATENTS

Docket Number	Country / Region	Application Number	Application Date	Publication Number	Patent Number	Grant Date
SOL-P06741	Canada	196783	07/07/2020			
SOL-P06742	Canada	196784	07/07/2020			
SOL-P06744	Canada	196782	07/07/2020			
SOL-P06741	China	202030365145.8	08/07/2020		ZL202030365145.8	10/11/2020
SOL-P06744	China	202030364689.2	08/07/2020		ZL202030364689.2	05/01/2021
SOL-P06741	EU Design	008031330-0001	03/07/2020		008031330-0001	03/07/2020
SOL-P06742	EU Design	008031330-0002	03/07/2020		008031330-0002	03/07/2020
SOL-P06743	EU Design	008031330-0003	03/07/2020		008031330-0003	03/07/2020
SOL-P06744	EU Design	008029581-0001	03/07/2020		008029581-0001	03/07/2020
SOL-P06741	GB	6094429	08/07/2020		6094429	08/07/2020
SOL-P06742	GB	6094430	08/07/2020		6094430	08/07/2020
SOL-P06743	GB	6094431	08/07/2020		6094431	08/07/2020
SOL-P06744	GB	6094367	07/07/2020		6094367	07/07/2020
SOL-P06741	Hong Kong	2016446.7	07/07/2020		2016446.7M001	07/07/2020
SOL-P06744	Hong Kong	2016447.9	07/07/2020		2016447.9	06/11/2020
SOL-P06741	Japan	2020-014061	09/07/2020		1676551	18/12/2020
SOL-P06742	Japan	2020-014062	09/07/2020		1686969	17/05/2021
SOL-P06743	Japan	2020-014064	09/07/2020		1687050	17/05/2021
SOL-P06744	Japan	2020-014063	09/07/2020		1680424	15/02/2021
SOL-P06741	Korea	30-2020-0030975-M001	07/07/2020		30-1122300-0001	02/08/2021
SOL-P06742	Korea	30-2020-0030975-M002	07/07/2020		30-1122300-0002	02/08/2021
SOL-P06743	Korea	30-2020-0030975-M003	07/07/2020		30-1122300-0003	02/08/2021
SOL-P06741	Mexico	MX/H/2020/001580	09/07/2020			

SOL-P06742		Mexico	MX/f/2020/001581	09/07/2020			
SOL-P06744		Mexico	MX/f/2020/001582	09/07/2020			
SOL-P06741		Russia	2020503108	09/07/2020		124147	12/05/2021
SOL-P06742		Russia	2020503109	09/07/2020		124751	13/04/2021
SOL-P06744		Russia	2020503110	09/07/2020		125628	31/05/2021
SOL-P06741		Thailand	2002003024	08/07/2020			
SOL-P06742		Thailand	2002003022	09/07/2020			
SOL-P06744		Thailand	2002003023	09/07/2020			
SOL-P06741		Taiwan	109303744	09/07/2020			
SOL-P06744		Taiwan	109303747	09/07/2020	D210466	D210466	11/03/2021
SOL-P06742	DOI	Taiwan	109303745DOI	26/03/2021		D213159	11/08/2021
SOL-P06742		Taiwan	109303745	09/07/2020		D211869	01/06/2021
SOL-P06741		United States	29/720106	09/01/2020		D921212	01/06/2021
SOL-P06742		United States	29/720107	09/01/2020		D922595	15/06/2021
SOL-P06743		United States	29/720109	09/01/2020		D928975	24/08/2021
SOL-P06744		United States	29/720111	09/01/2020			

PATENT

REEL: 058011 FRAME: 0912

RECORDED: 11/03/2021